Most studies to elucidate the role of antibody dependent cellular cytotoxicity (ADCC) have examined polyclonal antisera. However, more recently there have been reports of monoclonal antibodies being active in such systems (Bernstein et al., 1980; Herlyn al., 1979) . This is important because monoclonal reagents obviate the inherent variability and heterogeneity of conventional antisera and permit a more accurate analysis of the effector cell populations responsible for ADCC against a variety of targets. Furthermore, these advantages enable different groups to compare results.
Since monoclonal antibodies have been found to be effective in suppressing the growth of human tumours in immune-deprived animals (Herlyn et al., 1980; Bernstein et al., 1980; Kirch & Hammerling, 1981) , we decided to investigate an ADCC assay with a view to using it as a more simple system to screen monoclonal antibodies for possible clinical use. To do this we examined killing of human breast cancer cells comparing polyclonal and monoclonal antisera. Human peripheral blood lymphocytes (HPBL) and human bone marrow were used as sources of effector cells. We considered the latter to be important in view of the possibilities of using monoclonal antibodies to kill cancer cells in bone marrow (Buckman et al., 1982) .
The two polyclonal antisera tested were (a) antiepithelial membrane antigen (anti-EMA) raised in rabbits and purified as previously reported and (b) an antiserum raised in mice against the cell line MCF-7. Anti-EMA was chosen because of its value in detecting metastatic breast cancer cells in the bone marrow (Dearnaley et al., 1981) . Anti-EMA and anti-MCF-7 were both used at a dilution of 1/100 in medium (RPMI 1640, Gibco, containing 2% foetal calf serum, kanomycin (Edwards et al., 1980) and LICR-LON-R1O (Anstee & Edwards, 1982) were chosen, the former because of its panepithelial staining and its role in clearing metastatic breast carcinoma cells from human bone marrow (Buckman et al., 1982) ; this antibody was used at a concentration of 1-2pg/200p1 of medium. LICR-LON-RIO was used as mouse ascitic fluid at a dilution of 1/100 in medium. This antiserum reacts with red cell glycophorin and was used as a control. Normal non-immunised rabbit serum at a dilution of 1/100 in medium was used as a negative control for the studies with polyclonal antisera.
[51Cr]-sodium chromate labelled human breast carcinoma cells were used as target cells (MDA-MB-231; Cailleau et al., 1974) .
HPBL effector cells were obtained from human volunteers and bone marrow effector cells from normal human donors. The blood or bone marrow was diluted 1:3 in PBS, carefully layered onto Ficoll-Hypaque, density 1.077 and 1.100 respectively and centrifuged at 500g for 20min. The interface was collected, washed with medium and the cells suspended in an appropriate volume of medium.
The ADCC assay was performed by pipetting labelled target cells into 96-well U-bottomed plates (Microtitre M24 AR) at a concentration of 2 x 104 cells per 50M1 of medium per well, adding 100p1 of antibody and incubating for 1 h at 4°C. The cells were then centrifuged at 5OOg for 5min and the supernatants removed. Different concentrations of effector cells in 1001 of medium were then added to each well to give effector cell:target cell ratios from 1:1 to 200:1. The plates were then incubated for 4 h at 37°C. After this time 50 p1 of medium was added to each well to disturb the cells. The plates were then spun at 500g for 10 min and 120 p1 of supernatant removed and counted in a gamma counter. Maximum 51Cr-release was obtained by incubating target cells with 1% NP40. Percentage specific lysis was calculated in the usual way using the formula: %specific lysis= experimental release-spontaneous release l00 maximum release-spontaneous release
The ability of LICR-LON-Fib-75 to mediate ADCC was investigated at a variety of effector cell: target cell (EC :TC) ratios using HPBL. Anti-EMA was used concurrently at the same EC:TC ratio in each experiment as a positive control ( Table I) . Maximum lysis achieved with LICR-LON-Fib-75 was 45% at an EC:TC ratio of 100: 1. In the same experiment at the same EC:TC ratio anti-EMA produced 61% lysis. HPBL were obtained from each of the bone marrow donors at the time of their marrow harvest and assayed for their ADCC effect; the percentage specific lysis was comparable to that achieved with HPBL from normal volunteers.
We have found that anti-EMA is a potent mediator of ADCC when HPBL are used as the source of effector cells. Although the monoclonal antibody LICR-LON-Fib-75 will also effect ADCC when HPBL are used, it does so to a lesser extent. Anti-EMA and not LICR-LON-Fib-75 will effect ADCC above control levels, when bone marrow is used as the source of effector cells. These results indicate that the failure of an antibody to mediate ADCC with bone marrow is partly a function of the antiserum used. However, as all assays were terminated at 4h, there remains the possibility that the difference in effector capability between bone marrow and peripheral blood lymphocytes is a function of reaction kinetics. This has not been investigated.
Nevertheless, the results obtained using LICR-LON-Fib-75 are of particular interest since this is the first monoclonal antibody which has been shown to be active in an ADCC assay where human effector cells have been used against human tumour cell targets and a reasonably high percentage specific lysis achieved. Previous attempts to demonstrate ADCC in such a system have not been successful (Nadler, Stashenko et al., 1980; Dillman, Sobol et al., 1982) .
Mouse bone marrow-derived effector cells have been shown to mediate ADCC against red blood cell targets (Berger and Amos, 1977) and tumour cells (Haskill & Fett, 1976; Bursuker et al., 1982) , but it has not previously been shown that human bone marrow can be active in an ADCC assay against human tumour cells. The clinical significance of this activity is highly speculative but may merit further investigation particularly when treatments aimed at clearing malignant cells from bone marrow, by systemic or in vitro monoclonal antibody therapy, are proposed.
